APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Inclusion Criteria:

1. Histologically or cytologically confirmed solid tumor or hematological malignancies

2. Life expectancy ≥ 3 months

3. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

4. QTc interval ≤ 450 ms in males, and ≤ 470 ms in females

5. Adequate hematologic function

6. International normalized Ratio (INR), Prothrombin Time (PT) or Activated Partial
Thromboplastin time (aPTT) ≤1.5 X ULN

7. Adequate renal and liver function

8. Willingness to use contraception

9. Ability to understand and willingness to sign a written informed consent form

10. Willingness and ability to comply with study procedures and follow-up examination

11. Have provided tissue for biomarker analysis from a newly or recently-obtained biopsy
of a tumor lesion not previously irradiated

Exclusion Criteria:

Patients who meet any of the following exclusion criteria are not to be enrolled in this
study.

1. Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior
to entering the study

2. Received hormonal, biologic (< 2 half-lives), small molecule targeted therapies or
other anti-cancer therapy within 21 days of study entry

3. Radiation or surgery within 14 days of study entry, thoracic radiation within 28 days
of study entry.

4. Has known active central nervous (CNS) metastases and/or carcinomatous meningitis.
Patients who have received prior radiotherapy for previous brain metastasis must have
discontinued steroids for 14 days prior to study entry and be clinically stable.

5. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not
recover to ≤ Grade 1 except alopecia

6. Requirement for corticosteroid treatment, with the exception of megestrol, local use
of steroid.

7. Use of therapeutic anticoagulants

8. International normalized ratio (INR) or activated partial thromboplastin time (APTT) ≥
1.5 x ULN

9. Concurrent treatment with an investigational agent or device within 28 days prior to
the first dose of therapy

10. Unstable angina, myocardial infarction, or a coronary revascularization procedure
within 180 days of study entry

11. Neurologic instability per clinical evaluation due to tumor involvement of the central
nervous system (CNS).

12. History of Bell's palsy

13. Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic
infections, or any other disease or condition associated with chronic inflammation

14. Active infection requiring systemic antibiotic/ antifungal medication,

15. Known or suspected Wilson's Disease.

16. Prior treatment with IAP inhibitors

17. History of hypersensitivity to paclitaxel, or any therapeutic antibody

18. Has an active autoimmune disease, or a documented history of autoimmune disease, or a
syndrome that requires systemic steroids or immunosuppressive agents.

19. Is on chronic systemic steroid therapy

20. Has received a live vaccine within 30 days prior to first dose.

21. Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow
transplant